Gastroesophageal Reflux Disease Overview

The chronic gastrointestinal disorder gastroesophageal reflux disease (GERD) is defined by the regurgitation of stomach contents into the oesophagus. With a prevalence of 20%, it is one of the most often diagnosed digestive illnesses in the US, causing a major economic burden in direct and indirect expenditures and negatively affecting quality of life. The esophagogastric junction barrier is disrupted in Gastroesophageal Reflux Disease due to a variety of different reasons that can be intrinsic, structural, or both, exposing the oesophagus to acidic gastric contents.

“Gastroesophageal Reflux Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroesophageal Reflux Disease Market.

The Gastroesophageal Reflux Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastroesophageal Reflux Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Gastroesophageal Reflux Disease treatment therapies with a considerable amount of success over the years. Gastroesophageal Reflux Disease Key players such as – HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others, are developing therapies for the Gastroesophageal Reflux Disease treatment 

• Gastroesophageal Reflux Disease Emerging therapies such as – IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others are expected to have a significant impact on the Gastroesophageal Reflux Disease market in the coming years.   
• Fexuprazan is an investigational P-CAB for the treatment of EE, a chronic and progressive condition that impacts millions of patients in the U.S. It is designed to block proton pumps from secreting gastric acid in the stomach. P-CABshave been shown to act more rapidly and suppress the secretion of acid more effectively and more durably than proton pump inhibitors (PPIs), which are the current standard of care for EE
• In October ,2021 Daewoong Pharmaceutical signed a deal potentially worth 99.1 billion won ($83.7 million) with Aghrass Healthcare Limited to license its Fexuprazan gastroesophageal reflux treatment. Under the agreement, the Jeddah, Saudi Arabia-based company will sell Fexuprazan in six Gulf Cooperation Council (GCC) countries: Saudi Arabia, United Arab Emirates, Bahrain by 2024, and Kuwait, Oman and Qatar by 2025.

Gastroesophageal Reflux Disease Pipeline Therapeutics Assessment

• Gastroesophageal Reflux Disease Assessment by Product Type
• Gastroesophageal Reflux Disease By Stage and Product Type
• Gastroesophageal Reflux Disease Assessment by Route of Administration
• Gastroesophageal Reflux Disease By Stage and Route of Administration
• Gastroesophageal Reflux Disease Assessment by Molecule Type
• Gastroesophageal Reflux Disease by Stage and Molecule Type

DelveInsight’s Gastroesophageal Reflux Disease Report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Gastroesophageal Reflux Disease Drugs Under Different Phases of Clinical Development Include:

• IN-C003: HK inno.N
• IN-C002: HK inno.N
• CKD-382: Chong Kun Dang Pharmaceutical
• IN-C004: HK inno.N
• AD-214: Addpharma
• JP-1366: Jeil Pharmaceuticals
• Naronapride: Renexxion
• Fexuprazan: Daewoong Pharmaceutical

Gastroesophageal Reflux Disease Emerging Drugs

Fexuprazan: Daewoong Pharmaceutical

Daewoong’s new potassium-competitive acid blocker (P-CAB), fexuprazan, reversibly inhibits the proton pump in the cannalicular membrane that secretes gastric acids. It is a proton pump inhibitor (PPI) of the next generation, which is used often to treat gastroesophageal reflux disease (GERD). The Phase III clinical trial results for the medicine have now been made public by the business. The debut of Daewoong Pharmaceutical is planned.

X842: Cinclus Pharma 

Potassium Competitive Acid Blocker (P-CAB), a new class of medications represented by X842, is a fast-acting regulator of intragastric pH by a different mode of action than PPIs. The H+, K+-ATPase in the parietal cell is competitively inhibited by X842, a member of the P-CAB class, which regulates gastric acid secretion. AstraZeneca first produced the P-CAB linaprazan, which is what X842 is a prodrug of.

JP-1366: Jeil Pharmaceuticals 

In order to treat gastro-oesophageal reflux illness, Jeil Pharmaceuticals and its subsidiary Onconic Therapeutics are working together to develop JP 1366, an oral formulation of an anti-ulcer drug. Proton pumps that release gastric acid from the stomach wall are blocked by JP-1366.

Get a Free Sample PDF Report to know more about Gastroesophageal Reflux Disease Pipeline Assessment- https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-pipeline-insight

Gastroesophageal Reflux Disease Pipeline Analysis:

The Gastroesophageal Reflux Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Gastroesophageal Reflux Disease treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastroesophageal Reflux Disease Treatment.
• Gastroesophageal Reflux Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastroesophageal Reflux Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastroesophageal Reflux Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Gastroesophageal Reflux Disease product details are provided in the report. Download the Gastroesophageal Reflux Disease pipeline report to learn more about the emerging Gastroesophageal Reflux Disease therapies

Gastroesophageal Reflux Disease Pipeline Market Drivers

Rising cases of Gastroesophageal Reflux Disease

• Rising incidence of heartburn across the globe
• Technological advancements that allow for speedier diagnosis

Gastroesophageal Reflux Disease Pipeline Market Barriers

• Loss of patent protection of several leading drugs
• Lack of approved therapies

Scope of Gastroesophageal Reflux Disease Pipeline Drug Insight    

• Coverage: Global
• Key Gastroesophageal Reflux Disease Companies: HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
• Key Gastroesophageal Reflux Disease Therapies: IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
• Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies
• Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers 

Request for Sample PDF Report for Gastroesophageal Reflux Disease Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Gastroesophageal Reflux Disease drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting